Osmotica Recalls Subpotent Methylphenidate Hydrochloride Extended-Release Tablets
Osmotica Pharmaceutical Corp is voluntarily recalling 10,064 bottles of subpotent Methylphenidate Hydrochloride Extended-Release Tablets nationwide.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or minor defects.
Plain-English summary
Osmotica Pharmaceutical Corp is voluntarily recalling 10,064 bottles of Methylphenidate Hydrochloride Extended-Release Tablets, USP 27 mg, 100-count bottles. The product is manufactured by Trigen Laboratories, LLC, located in Bridgewater, NJ, and carries the NDC 13811-707-10. The specific lot affected is 170027A, with an expiration date of 02/2019.
The recall was initiated because the product was found to be subpotent, meaning it did not contain the full amount of the active ingredient required by the United States Pharmacopeia (USP) standards. This is a Class III recall, which indicates that the violation is not likely to cause adverse health consequences. The recall is voluntary and was initiated by the firm.
The affected product was distributed nationwide. Consumers and healthcare providers should check their inventory for the specific lot number and expiration date listed above. If the product is found, it should be returned to the pharmacy or point of purchase for a refund or replacement. No specific instructions for disposal are provided in the source text, but standard pharmacy return procedures apply.
The recalled product
- Product
- METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE)
- Brand
- METHYLPHENIDATE HYDROCHLORIDE
- Manufacturer
- Osmotica Pharmaceutical Corp
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 10,064
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 170027A
- Exp. 02/2019
UPCs (2)
- 0313811706109
- 0313811708103
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Osmotica Pharmaceutical Corp under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · METHYLPHENIDATE HYDROCHLORIDE
- HighMethylphenidate Hydrochloride Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2024-07-10
- HighMethylphenidate Hydrochloride Tablets Recalled Due to Metal Contamination
FDA (Drugs) · 2023-08-02
- ModerateMethylphenidate Hydrochloride Chewable Tablets Recalled for Failed Specifications
FDA (Drugs) · 2022-03-02
- ModerateTeva Recalls Methylphenidate Hydrochloride Extended-Release Tablets Due to Missing Desiccant
FDA (Drugs) · 2020-02-19
- ModerateTeva Recalls Methylphenidate Hydrochloride Extended-Release Tablets Due to Missing Desiccant
FDA (Drugs) · 2020-02-19
Same manufacturer · Osmotica Pharmaceutical Corp
See all →- ModerateOsmotica Recalls Subpotent Methylphenidate Hydrochloride Extended-Release Tablets
FDA (Drugs) · 2018-03-14
- ModerateOsmotica Recalls Subpotent Methylphenidate Hydrochloride Extended-Release Tablets
FDA (Drugs) · 2017-12-27
- LowOsmotica Recalls Venlafaxine Extended Release Tablets for Dissolution Failure
FDA (Drugs) · 2013-10-09
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02